DaVita reports Q4 adjusted EPS $3.40, consensus $3.19

Reports Q4 revenue $3.62B, consensus $3.51B. “Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment,” said Javier Rodriguez, CEO of DaVita (DVA). “Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond.”